Boston Scientific logo

Boston Scientific Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Boston Scientific holds $44.4B in total assets. Cash and equivalents total $850.0M. The current ratio is 1.90. Based on the Q1 2026 filing.

Latest FilingQ1 2026
Report Date2026-05-01
Market Cap$83.1B
P/E Ratio23.35
ROE14.81%

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Allowance for doubtful accounts$109.0M$113.0M$112.0M$133.0M$132.0M$127.0M
Business Combination, Contingent Consideration, Liability$171.0M$214.0M$367.0M$378.0M$385.0M$354.0M
Common stock, par value (in dollars per share)$0.01$0.01$0.01$0.01$0.01$0.01
Common stock, shares authorized (in shares)2B2B2B2B2B2B
Common stock, shares issued (in shares)1.7B1.7B1.7B1.7B1.7B
Construction work in progress$1.0B$1.0B$1.0B$936.0M$1.2B$1.1B
Contract with Customer, Liability$635.0M$641.0M$662.0M$668.0M$682.0M$686.0M
Short-term debt and current portion of long-term debt$1.8B$777.0M$480.0M$483.0M$299.0M$41.0M
Debt Instrument, Fair Value Disclosure$10.3B$10.9B$11.3B$11.2B$11.2B$10.6B
Deferred income taxes$155.0M$158.0M$226.0M$242.0M$220.0M$219.0M
Derivative, gross, assets$384.0M$232.0M$91.0M$125.0M$181.0M$219.0M
Derivatives, gross, liabilities$990.0M$1.0B$1.4B$1.3B$1.3B$1.2B
Derivative Liability$1.3B$1.2B
Notional$8.6B$10.5B$11.8B$13.1B$13.7B$14.6B
Equipment, furniture and fixtures$3.6B$3.8B$3.9B$4.0B$3.8B$3.9B
Difference between equity method investment carrying value and book value$374.0M$321.0M$375.0M$334.0M
Equity method investments (Note 11)$278.0M$358.0M$334.0M$334.0M$396.0M$309.0M
Finite-Lived Intangible Assets, Accumulated Amortization$10.6B$10.8B$11.0B$11.2B$11.5B$11.7B
Gross Carrying Amount$17.2B$17.3B$17.4B$17.6B$17.7B$18.0B
Goodwill, Gross$27.0B$27.2B$28.0B$28.1B$28.2B$28.4B
Goodwill accumulated impairment losses$9.9B$9.9B$9.9B$9.9B$9.9B$9.9B
Legal payments remaining to be excluded from calculation of consolidated EBITDA$1.4B$1.4B$1.4B$1.1B
Letters of Credit Outstanding, Amount$206.0M$218.0M$220.0M$223.0M$203.0M$193.0M
Licensing arrangements, liability$7.0M$0.0
Litigation payment exclusion from EBITDA$1.0B$1.0B$1.0B$1.2B
Long-Term Debt and Lease Obligation$9.0B$10.5B$11.1B$11.1B$11.1B$11.0B
Loss Contingency Accrual$326.0M$316.0M$300.0M$306.0M$242.0M$229.0M
Noncontrolling interests in subsidiaries$233.0M$233.0M$235.0M$236.0M$239.0M$240.0M
Money Market Funds At Carrying Value$1.1B$684.0M
Long-Lived Assets$27.5B$27.7B$29.3B$29.7B$29.8B$30.2B
Preferred Stock, Par or Stated Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Preferred Stock, Shares Authorized50M50M50M50M50M50M
Preferred Stock, Shares Issued000000
Restricted cash equivalents included in Other long-term assets$80.0M$91.0M$98.0M$103.0M$119.0M
Share Repurchase Program, Authorized, Amount$4.0B
Treasury stock, shares (in shares)263.3M263.3M263.3M263.3M263.3M263.3M
Uncapped Contingent Considertation$151.0M$106.0M$115.0M$132.0M
Unrecognized tax benefits$506.0M$514.0M$531.0M$529.0M$596.0M$609.0M
Amount that if recognized, would affect the effective tax rate or regulatory liability$423.0M$431.0M$447.0M$444.0M$501.0M$512.0M